OTC : HKMPF

Hikma Pharmaceuticals PLC

$20.37 USD

-$0.89 (-4.19%)

Volume
450
Average Volume
196
Market Capitalization
$4.29B
P/E Ratio
0.19
Dividend Yield
4.01%
Price Target
Year High
$27.96
Year Low
$16.34
Day High
—
Day Low
—
Payout Ratio
$0.45
Current Ratio
$1.82
Company Overview

OTC

Said Samih Taleb Darwazah

Drug Manufacturers - Specialty & Generic

Healthcare

HKMPF

9400

GB

USD

https://www.hikma.com

44 20 7399 2760

N/A

N/A

Liquidity Metrics

0.62

1.82

1.06

0.23

0.45

Sales & Valuation

$3.35B

1.30

1.75

22.36

0.88

Profitability

$1.85

$410.94M

12.00%

15.49%

15.83%

7.10%

P/E Metrics

0.19

0.00

0.00

Analyst Price Target & Rating

Buy

4/5

2 Analysts

%

Financial Health Scores

3.65

7/9

$1.19B

$5.68B

$3.07B

$1.29B

Key Metrics (TTM)

$5.63B

1.68

8.40

1.82

15.83%

10.21%

8.84%

4.47%

$22.03

190 days

Company Executives
Name Title
Said Samih Taleb Darwazah Chief Executive Officer
Areb KURDI VP, Group Financial Controller & Acting CFO
Bassam Wael Rushdi Kanaan Executive Vice President of Corporate Development and M&A
Guy Featherstone Associate Director of Investor Relations
Hussein Arkhagha Chief People Officer
Khalid Walid Hussni Al Nabilsi Deputy CEO of North America and Europe & Director
Mazen Samih Taleb Darwazeh Executive Vice Chairman & Deputy CEO of MENA
Samuel Park General Counsel
Julie Hill Senior Vice President of Corporate Quality Compliance/Health & Safety
Patricia Bousfield Chief Information Officer
Susan Ringdal Executive Vice President of Strategic Planning & Global Affairs
Poll Results

No votes yet today — be the first to share your view!

About Hikma Pharmaceuticals PLC (OTC:HKMPF) Stock

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spa ... nning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.

Citi starts Hikma at 'buy' with strategy reset offering compelling entry point

2026-07-16 07:21:56

Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry point. The 12-month target, based on a sum-of-the-parts valuation, implies a share price return of around 14%.

London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four

2026-07-16 06:30:00

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the...

AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion

2026-07-16 04:41:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...

Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval

2026-07-16 04:37:00

Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...

Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript

2026-04-23 06:51:32

Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript

UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war

2026-04-23 02:27:19

Hikma Pharmaceuticals reiterated ​its 2026 ‌guidance on Thursday, adding ​that, while ​it has faced ⁠some pressure ​on shipping, ​energy, and insurance costs due ​to the ​war in the ‌Middle ⁠East, a key market for the ​firm, ​it ⁠was confident it ​could ​absorb ⁠the higher costs.

Frequently Asked Questions

What is the current Hikma Pharmaceuticals PLC (HKMPF) stock price?

Hikma Pharmaceuticals PLC(OTC:HKMPF) stock price is $20.37 in the last trading session. During the trading session, HKMPF stock reached the peak price of $27.96 while $16.3425 was the lowest point it dropped to. The percentage change in HKMPF stock occurred in the recent session was --4.19% while the dollar amount for the price change in HKMPF stock was -$0.89.

HKMPF's industry and sector of operation?

The OTC listed HKMPF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of HKMPF?

Said Samih Taleb Darwazah | Chief Executive Officer
Areb KURDI | VP, Group Financial Controller & Acting CFO
Bassam Wael Rushdi Kanaan | Executive Vice President of Corporate Development and M&A
Guy Featherstone | Associate Director of Investor Relations
Hussein Arkhagha | Chief People Officer

How many employees does HKMPF have?

Number of HKMPF employees currently stands at 9400. HKMPF operates from 10 Portman Square, London, GL W1H 6AZ, GB.

Link for HKMPF official website?

Official Website of HKMPF is: https://www.hikma.com

How do I contact HKMPF?

HKMPF could be contacted at phone #44 20 7399 2760 and can also be accessed through its website. HKMPF operates from 10 Portman Square, London, GL W1H 6AZ, GB.

How many shares of HKMPF are traded daily?

The average number of HKMPF shares traded daily for last 3 months was 196.

What is the market cap of HKMPF currently?

The market value of HKMPF currently stands at $4.29B with its latest stock price at $20.37